Sera Prognostics, Inc. · NASDAQ:SERA
Sera Prognostics — Investor Presentation (September 2025)
31 slides from Sera Prognostics's investor presentation, Sep 5, 2025
Slide 1: We are redefining pregnancy care to reduce the burden of preterm birth
September 2025 We are redefining pregnancy care to reduce the burden of preterm birth Exhibit 99.1
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue
Slide 3: Our Bold Ambition
Our vision is to become a global leader in high-value women’s health diagnostics. We’ll do this by taking a holistic approach to providing pivotal information to providers and patients—simultaneously enabling better health for moms and babies while improving the economics of healthcare delivery. Our
Slide 4: Corporate Overview
Reference: 1. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2022. Natl Vital Stat Rep. 2024 Apr;73(2):1-56. PMID: 38625869 2 Martin JA, Osterman MJK. Increases in neonatal intensive care admissions in the United States, 2016–2023. NCHS Data Brief. 2025 Mar;
Slide 5: The Need
THE Need
Slide 6: The US Has a Premature Birth Problem
THE US HAS A PREMATURE BIRTH PROBLEM And identification isn’t getting better National Vital Statistics Data: Infants were more likely to be admitted to a NICU in 2023 than in 2016, according to the Centers for Disease Control. The percentage of infants admitted rose from 8.7% to 9.8% FROM 2013-20233
Slide 7: Premature Birth Leads to 18x+ Higher Birth Cost of Newborns
HEALTH CARE COSTS OVER 7 YEARS Health Cost & Implications PREMATURE BIRTH LEADS TO 18X+ HIGHER BIRTH COST OF NEWBORNS Extremely Premature < 28 weeks Risk of death, long NICU stay, respiratory issues, decreased organ development, infections Premature < 32 weeks Respiratory issues, significant NICU s
Slide 8: Majority of Premature Deliveries Not Identified Using Current Methods
THE MAJORITY OF PREGNANT WOMEN who deliver prematurely are not identified using current methods Reference: 1. Everyday Health Group Pregnancy & Parenting Insights, Bump Day Survey 2022; Q: “At your first prenatal appointment, what written materials did your doctor provide you with?” Saade GR, et al.
Slide 9: Product and Science
PRODUCT AND Science
Slide 10: What is a Proteomic Test?
THE PURPOSE Predictive test to detect biomarkers in the blood before symptoms arise WHAT IT MEASURES Risk of developing a condition, and biological effect HOW IT WORKS Uses advanced technologies (mass spectrometry) to analyze proteins and reveals patterns of protein expression and modification THE S
Slide 11: Blood-Based Biomarkers
BLOOD-BASED BIOMARKERS Specific proteins are associated with preterm birth risk IGFBP4 Insulin-like Growth Factor Binding Protein-4 Nutrient Delivery Reference: Saade GR, Boggess et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol
Slide 12: Determine a Mom's Risk of Spontaneous Preterm Birth
EVEN IF SHE LACKS EVIDENT RISK FACTORS Determine a Mom’s risk of spontaneous preterm birth to improve outcomes NOT HIGHER RISK
Slide 13: PreTRM Integrates With a Women's Health Clinic Workflow
Results delivered in an average of five days from a CLIA-certified, CAP-accredited lab Blood sample kits are provided for testing during 180/7-206/7 weeks with prepaid shipment to Sera’s lab Sample collection can be performed by staff and aligns with preexisting appointments ©2025 Sera Prognostics,
Slide 14: PreTRM Test Report
Pregnancies identified as higher risk by the PreTRM Test are at increased risk for*: Communicates a patient’s risk of spontaneous preterm birth & helps physicians engage with patients TEST REPORT Spontaneous preterm birth Severe adverse neonatal outcomes Longer neonatal hospital length of stay Refer
Slide 15: Robust Clinical Evidence
Evidence ROBUST CLINICAL
Slide 16: Sera Drives Strategic Advantage to Deliver Clear Insights
Sera Drives Strategic Advantage to Deliver Clear Insights Biobank of Blood Samples Rich Portfolio of Evidence Demographic & Geographic Diversity Advanced Mass Spectrometry Artificial Intelligence & Machine Learning Global Dataset 20,000 pregnant women 11+ Published Studies; PRIME Pending Broad sampl
Slide 17: PreTRM Test Only Clinically Validated Test for Early Prediction
THE PRETRM® TEST IS THE ONLY CLINICALLY VALIDATED TEST AVAILABLE FOR EARLY PREDICTION OF PREMATURE BIRTH PAPR Validation Study1 (n=5501, 11 centers) The PreTRM® Test is highly predictive of spontaneous preterm birth with a single blood draw during 180/7 through 206/7 weeks of gestation2 Three Indepe
Slide 18: PRIME Abstract and AVERT Study
PRIME ABSTRACT The Randomized Controlled Trial Involved: 19 U.S. sites, including community practices and university-based or -associated medical centers Enrolled 5018 patients Presented at SMFM Annual Meeting 2025 From November 2020 – December 2023 AVERT STUDY The Historically Controlled Trial Invo
Slide 19: PreTRM Shown More Effective in Reducing Neonatal Impacts
PreTRM® Test shown in clinical validation studies to be more effective in reducing neonatal impacts than current measures Number (of mothers) Needed to Screen to prevent NICU admission: comparison between widely adopted screening vs PreTRM: lower number indicates greater efficiency Transvaginal Ultr
Slide 20: The PRIME Abstract
THE PRIME ABSTRACT Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal OutcoMEs PRIME Most Recent Evidence Shows Efficacy Across Different Populations A pioneering clinical trial assessing the efficacy of the PreTRM Test and preventive interventions in lowering th
Slide 21: PRIME and AVERT Demonstrated High Clinical Utility
PRIME ABSTRACT + AVERT STUDY DEMONSTRATED HIGH CLINICAL UTILITY Studies Show PreTRM Test Significantly Improves Neonatal Outcomes LOWER NEONATAL MORBIDITY & MORTALITY 20% reduction in neonatal morbidity and mortality DECREASE IN NICU ADMISSIONS AND LENGTH OF STAY There was a 22% decrease in NICU adm
Slide 22: Evidence-Based, Targeted Interventions
EVIDENCE-BASED, TARGETED INTERVENTIONS FROM PRIME ABSTRACT & AVERT STUDY Clear direction on managing higher risk pregnancies complementary with guidelines Low-Dose Aspirin (81 mg) Taken orally daily until 366/7 weeks gestation Vaginal Progesterone (200 mg) Administered daily as a 200 mg micronized p
Slide 23: Pathway to Commercialization
PATHWAY TO Commercialization
Slide 24: The PreTRM Test Ushers in a New Era of Personalized Pregnancy Care
Ushers in a new era of personalized pregnancy care THE PRETRM® TEST
Slide 25: Entering Commercialization Stage
WITH PRIME PUBLICATION We Are Entering Commercialization Stage Follows Key Milestones (Guidelines, Reimbursement) Market Adoption % R&D SERA FOUNDED 2025 PRIME STUDY EXPECTED Broad Market Adoption Clinical Validation & Evidence Generation Targeted Adoption INFLECTION POINT ILLUSTRATIVE Revenue TODA
Slide 26: Key 12-24 Month Revenue Acceleration Initiatives
KEY 12-24 MONTH REVENUE ACCELERATION INITIATIVES Geographic Focus: Investment in driving volume Additional Key Account Managers & Payer Staff Continue institutional (large hospitals and IDN) conversations, armed with PRIME data Pilots focus on state level Medicaid programs Develop individualized pro
Slide 27: Health Economic Data: Reaching Payers
Illustrative impact for example small insurance plan 95% Confidence Interval Cumulative Net Impact Key assumptions: Covered lives: 812,000 Pregnancies/year: 8,607 Eligible for test: 88%; Screen Positive: 24% Intervention acceptance: 65% Cost: Test=$750 Cost of intervention=$1,200 Savings per person
Slide 28: Reaching Moms with Premature Birth Education
Reaching Moms with Premature Birth Education WEEK 15 EMAIL PreTRM.com JAN 01 – AUG 04 REACH OF US PREGNANT WOMEN 80% MONTHLY VISITORS 1.1MM 93% REACH OF FIRST TIME MOMS EVERYDAYHEALTH DIGITAL PARTNERSHIP 2025 SESSIONS: 161,309 2024 SESSIONS: 72,404
Slide 29: (©2026 Sera Prognostcs, ne. Al rights reserved. PreTRM, Sera Prognostcs and thelr logos are
© SERA (©2026 Sera Prognostcs, ne. Al rights reserved. PreTRM, Sera Prognostcs and thelr logos are trademarks or registered trademarks of Sera Prognostes, nc. nthe United States
Slide 30: Sera Leadership
Sera Leadership Zhenya Lindgardt President & CEO Former VP of Platform & Customer Engagement, Uber Technologies Former Senior Partner & Managing Director, The Boston Consulting Group Former CEO, The Commons Project Foundation MBA, Harvard University Former VP, Finance & Corporate Controller, Sera Fo
Slide 31: Together, We Can Do Better
Educate Providers. Empower Moms. HELP Babies. Advance Science. Elevate Care. Reach Maternity Deserts. Inform Payers. Evoke Change. TOGETHER, WE CAN DO BETTER PRESENT-105 / 08-25
Sera Prognostics — Investor Presentation (September 2025) on 6ix